

20. (New) The method of claim 19, wherein the residue at position 31 of said amino acid sequence of said null IGF-I is a non-aromatic residue.

21. (New) The method of claim 1, wherein the residues at positions of 24, 31 and 60 of the amino acid sequence of said null IGF-I are altered to a non-aromatic residue.

22. (New) The method of claim 1, wherein the amino acid sequence of said null IGF-I is altered such that residues 28 to 37 are replaced with four glycine residues.

23. (New) The method of claim 22, wherein the residue at position 60 of the amino acid sequence of said null IGF-I is a non-aromatic residue.

24. (New) The method of claim 22, wherein the residue at position 24 of the amino acid sequence of said null IGF-I is a non-aromatic residue.

25. (New) The method of claim 7, wherein said cancer is breast cancer.

26. (New) The method of claim 7 or 18, wherein said cancer is prostate cancer.

27. (New) The method of claim 7, wherein said cancer is colon cancer.

28. (New) The method of claim 7, wherein said cancer is lung cancer.

29. (New) The method of claim 8, wherein said cancer is breast cancer.

30. (New) The method of claim 8, wherein said cancer is prostate cancer.

31. (New) The method of claim 8, wherein said cancer is colon cancer.

32. (New) The method of claim 8, wherein said cancer is lung cancer.

33. (New) The method of claim 19, wherein said cancer is breast cancer.

34. (New) The method of claim 19, wherein said cancer is prostate cancer.

35. (New) The method of claim 19, wherein said cancer is colon cancer.

36. (New) The method of claim 19, wherein said cancer is lung cancer.

37. (New) The method of claim 20, wherein said cancer is breast cancer.